Database

VITAMFERO

Solution provided
Technology
Supplier identity
General description

Incorporated in late 2005, VitamFero SA is a privately held biotech company whose mission, founded on an innovative and patented technology (i.e. Toxo KO), is to create, develop, register and market novel anti-infectious vaccines, first against Apicomplexe parasites such as:

- Toxoplasma gondii (toxoplasmosis agent)
- Neospora caninum (neosporosis agent)
 - Cryptosporidium parvum (cryptosporidiosis agent).

Region
Regions of Pays de la Loire, Centre and Poitou-Charentes, FR
Regional access broker
  • Grégory Bauer, Atlanpole Biotherapies
Activity description
Services provided

Patented technology based on a live and attenuated Toxoplasma gondii strain, the parasite responsible for toxoplasmosis.  This strain, called "Toxo KO", was obtained by dual deletions (hence Knock-Out or KO) of mic1 and mic3 genes through a homologous recombination procedure.  Despite the lack of MIC1 and MIC3 protein expression, the "Toxo KO" strain remains fully viable and, most of all, it is non-pathogenic while keeping its strong immunogenic potentialities.

Training and Staff possibilities
No
Contact information
Name
BRETON
Surname
Pascal
Function
CEO
Phone number
+33 (0)2 47 36 70 47
Address
Université François Rabelais de Tours
31 avenue Monge
37200  TOURS
France